JPH07328111A - Sterilization method of blood purifier - Google Patents
Sterilization method of blood purifierInfo
- Publication number
- JPH07328111A JPH07328111A JP6126401A JP12640194A JPH07328111A JP H07328111 A JPH07328111 A JP H07328111A JP 6126401 A JP6126401 A JP 6126401A JP 12640194 A JP12640194 A JP 12640194A JP H07328111 A JPH07328111 A JP H07328111A
- Authority
- JP
- Japan
- Prior art keywords
- blood purifier
- sterilization
- semipermeable membrane
- blood
- membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 48
- 239000008280 blood Substances 0.000 title claims abstract description 48
- 230000001954 sterilising effect Effects 0.000 title claims abstract description 43
- 238000004659 sterilization and disinfection Methods 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims abstract description 27
- 239000012528 membrane Substances 0.000 claims abstract description 54
- 239000007864 aqueous solution Substances 0.000 claims abstract description 18
- 230000005855 radiation Effects 0.000 claims description 20
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 8
- 230000006866 deterioration Effects 0.000 abstract description 19
- 229920002678 cellulose Polymers 0.000 abstract description 7
- 239000001913 cellulose Substances 0.000 abstract description 7
- 230000009467 reduction Effects 0.000 abstract description 3
- 230000002285 radioactive effect Effects 0.000 abstract 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 abstract 2
- 230000032683 aging Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 description 19
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000012510 hollow fiber Substances 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 229910001385 heavy metal Inorganic materials 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 239000000306 component Substances 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000004627 regenerated cellulose Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000035699 permeability Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- -1 polyethylene copolymer Polymers 0.000 description 4
- 229920002284 Cellulose triacetate Polymers 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229920002301 cellulose acetate Polymers 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000005251 gamma ray Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 229920003174 cellulose-based polymer Polymers 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012611 container material Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000004382 potting Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229920002803 thermoplastic polyurethane Polymers 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、人工臓器等に用いられ
る半透膜からなる血液浄化器の滅菌方法に関するものな
のである。さらに詳しくは、放射線による滅菌処理に伴
う素材劣化を低減させた半透膜を提供するための血液浄
化器の滅菌方法に関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for sterilizing a blood purifier having a semipermeable membrane used for artificial organs and the like. More specifically, the present invention relates to a method for sterilizing a blood purifier for providing a semipermeable membrane in which deterioration of materials due to radiation sterilization treatment is reduced.
【0002】[0002]
【従来の方法】従来、医療分野においては、血液中の老
廃物を除去する目的で再生セルロース・酢酸セルロース
等のセルロース系高分子、ポリメチルメタクリレート・
ポリアクリロニトリル・ポリスルホン・ポリビニルアル
コールーポリエチレン共重合体等の合成高分子系重合体
の素材を用いた透析膜、及び限外濾過膜が用いられてい
る。これらの素材は、血液浄化器としての優れた血液成
分に対する溶質透過性と共に機械的強度についての要求
特性を満足している必要がある。Conventionally, in the medical field, cellulose-based polymers such as regenerated cellulose and cellulose acetate, polymethylmethacrylate
BACKGROUND ART A dialysis membrane and an ultrafiltration membrane using a material of a synthetic polymer such as polyacrylonitrile / polysulfone / polyvinyl alcohol / polyethylene copolymer are used. It is necessary that these materials satisfy the required properties of mechanical strength as well as excellent solute permeability for blood components as a blood purifier.
【0003】また近年、医療用材料が血液と接触するこ
とにより引き起こされる種々の問題が提示され、血液浄
化膜においては、血液体外循環治療が比較的長期間を要
するなどの面から重要な解決すべき問題として、例え
ば、血液透析時の白血球の一過性減少・補体成分の活性
化の問題等が指摘されており、生体適合性として血液浄
化膜の善し悪しの重要な指標となっている。Further, in recent years, various problems caused by contact of medical materials with blood have been presented, and in blood purification membranes, extracorporeal blood treatment for blood requires a relatively long period of time, which is an important solution. As problems to be solved, for example, transient reduction of white blood cells during hemodialysis, activation of complement components, etc. have been pointed out, and they are important indicators of goodness and badness of blood purification membrane as biocompatibility.
【0004】かかる問題にたいしては、再生セルロース
からなる膜は、その重合体分子の中に有する水酸基によ
り血液中の補体が活性化されることから、生体適合性に
ついては満足できる素材とは言えない。この点について
は、修飾セルロースや、合成高分子は優れた特性を有し
ている。With respect to such a problem, a membrane made of regenerated cellulose cannot be said to be a satisfactory material in terms of biocompatibility since the complement in blood is activated by the hydroxyl group contained in the polymer molecule. . In this regard, modified cellulose and synthetic polymers have excellent properties.
【0005】また一方、血液浄化器は、医療用途を使用
対象としていることから、無菌性に対する保証が必要と
なる。通常は、その製造過程からできうるかぎり無菌的
に管理され、最終的に滅菌処理を施した後使用に供され
る。On the other hand, since the blood purifier is intended for medical use, it is necessary to guarantee sterility. Usually, it is aseptically controlled as much as possible from the manufacturing process, and finally subjected to sterilization treatment before use.
【0006】血液浄化器の滅菌方法として、現在一般に
用いられている方法は、ホルマリン滅菌、エチレンオキ
サイドガス滅菌(以下、EOG滅菌と略する)、放射線
滅菌、高圧蒸気滅菌などである。ホルマリン滅菌では、
血液浄化器に一定濃度以上ホルマリン水溶液を充填し滅
菌効果を得ようとするものであるが、使用時の残留ホル
マリンの毒性が問題となる。このため使用時には、ホル
マリンの排出に長時間大量の無菌水を流通させることが
要求され、完全に残留をなくすことは難しい。また、血
液浄化器の製造時にこれらの処理を行うことは、製造工
程を極めて煩雑にし、かえって安全性を低下しかねな
い。従ってホルマリン滅菌法は、現在では殆ど病院内な
ど医療の現場での臨時の場合や、血液浄化器の再使用に
伴う再生滅菌法としてのみ用いられている。As a sterilizing method for blood purifiers, methods generally used at present are formalin sterilization, ethylene oxide gas sterilization (hereinafter abbreviated as EOG sterilization), radiation sterilization, high pressure steam sterilization and the like. With formalin sterilization,
Although a blood purifier is filled with an aqueous solution of formalin at a certain concentration or higher to obtain a sterilizing effect, the toxicity of residual formalin during use poses a problem. For this reason, when used, it is required to circulate a large amount of sterile water for a long time to discharge formalin, and it is difficult to completely eliminate the residue. In addition, performing these treatments at the time of manufacturing the blood purifier makes the manufacturing process extremely complicated and may rather reduce the safety. Therefore, the formalin sterilization method is currently used almost exclusively in the case of medical treatment such as in a hospital or as a regenerated sterilization method accompanying reuse of the blood purifier.
【0007】EOG滅菌法は、血液浄化器をエチレンオ
キサイドガス(EOG)雰囲気中に置き、EOGの菌に
対する殺傷作用で滅菌するものである。しかし、EOG
滅菌では、血液浄化器に僅かに残留するEOGが人体に
対してアレルギー作用を示すことがあり、完全に脱ガス
することが必要であると共に、人によってはEOG滅菌
処理した装置は使えない場合もある。また当然、EOG
に対して反応性を有する素材で装置が構成されている場
合は使用できない。According to the EOG sterilization method, a blood purifier is placed in an ethylene oxide gas (EOG) atmosphere and sterilized by killing the bacteria of EOG. However, EOG
In sterilization, a small amount of EOG that remains in the blood purifier may have an allergic effect on the human body, and it is necessary to completely degas it, and some people may not be able to use the EOG-sterilized device. is there. And of course, EOG
It cannot be used when the device is made of a material that is reactive to.
【0008】高圧蒸気滅菌は、通常115℃〜130℃
の飽和水蒸気中で数十分〜一時間程度処理することで達
成される。しかしながら、比較的熱に対する安定性の低
い素材を用いた血液浄化器の場合は、熱滅菌での高温、
高湿処理によって半透膜の構造が変化しやすく、透過の
性能が著しく低下することが知られている。High-pressure steam sterilization is usually 115 ° C to 130 ° C.
It can be achieved by treating the saturated steam for several tens of minutes to one hour. However, in the case of a blood purifier using a material having relatively low heat stability, high temperature during heat sterilization,
It is known that the high-humidity treatment tends to change the structure of the semipermeable membrane, resulting in a significant decrease in permeation performance.
【0009】放射線滅菌は、ホルマリン、EOGなどの
物質の作用による菌への殺傷効果に基づくものと異な
り、血液浄化器に特殊な注入、排出の操作を施すことな
く完全な密封系で滅菌処理ができる方法として用いられ
ている。その設備は、大なるものがあるが、滅菌保証力
は、滅菌原理の上からも容易かつ確実で、他の方法をは
るかに上回るものがある。その反面、放射線の高エネル
ギーによる血液浄化器の膜素材やケース部材の劣化の懸
念がもたれている。しかし、その特性を把握し、製造条
件を選択すれば劣化を最小限に抑え、医療用具としての
安全性はじゅうんに確保でき、滅菌保証力の確かさを十
分に発現できる滅菌法であると言える。Radiation sterilization is different from the one based on the killing effect on bacteria due to the action of substances such as formalin and EOG, and the sterilization treatment can be performed in a completely sealed system without special injection and discharge operations to the blood purifier. It is used as a possible method. The equipment is large, but the sterilization assurance power is easy and reliable from the viewpoint of the sterilization principle, and far exceeds other methods. On the other hand, there is concern about deterioration of the membrane material and case member of the blood purifier due to high energy of radiation. However, if the characteristics are grasped and the manufacturing conditions are selected, deterioration can be minimized, the safety as a medical device can be sufficiently secured, and the sterilization method can sufficiently demonstrate the assurance of sterilization ability. I can say.
【0010】放射線(γ線)により滅菌する場合は、滅
菌前の汚染菌数とγ線照射に対する細菌の耐性を示すD
値により照射線量が決定される。現在での線量はこの評
価により、25kGyが一般的である。血液浄化器では
製造工程の改善により、滅菌前の汚染菌数の低減が図ら
れ、滅菌線量の低減がなされつつある。しかしながら、
現状の最低線量とされる20kGyでも、血液浄化膜の
劣化を完全に無視できるところまでは至っていないのが
実状であり、汚染菌数をさらに低減する点もほぼ限界に
ある。このような理由により、照射線量を下げることな
く、かつ材料劣化を抑えることができる放射線滅菌処理
方法の開発が要求されている。When sterilized by radiation (γ ray), the number of contaminating bacteria before sterilization and the resistance of bacteria to γ ray irradiation D
The value determines the irradiation dose. Based on this evaluation, the current dose is generally 25 kGy. In blood purifiers, the number of contaminating bacteria before sterilization has been reduced by improving the manufacturing process, and the sterilization dose is being reduced. However,
Even with the current minimum dose of 20 kGy, the fact is that the deterioration of the blood purification membrane has not been completely neglected, and the point of further reducing the number of contaminating bacteria is almost at the limit. For these reasons, there is a demand for the development of a radiation sterilization method that can suppress material deterioration without reducing the irradiation dose.
【0011】[0011]
【発明が解決しようとする課題】本発明の目的は、半透
膜からなる血液浄化器において、半透膜劣化の低減され
放射線滅菌方法を提供することにある。SUMMARY OF THE INVENTION An object of the present invention is to provide a method for sterilizing radiation in a blood purifier having a semipermeable membrane, in which deterioration of the semipermeable membrane is reduced.
【0012】[0012]
【課題を解決すための手段】前記問題点を解決した半透
膜を用いた血液浄化器の放射線滅菌法を提供するため鋭
意研究し結果、本発明に到達した。すなわち、本発明
は、半透膜を用いた血液浄化器において、血液浄化器内
部に多価カルボン酸の水溶液を充填密閉し、該半透膜が
多価カルボン酸水溶液により浸漬された状態で放射線滅
菌を施すことを特徴する血液浄化器の滅菌方法である。Means for Solving the Problems The present invention has been achieved as a result of intensive research to provide a radiation sterilization method for a blood purifier using a semipermeable membrane that solves the above problems. That is, the present invention is a blood purifier using a semipermeable membrane, filled and sealed with an aqueous solution of a polyvalent carboxylic acid inside the blood purifier, and the semipermeable membrane is immersed in the aqueous solution of the polyvalent carboxylic acid for radiation. It is a method of sterilizing a blood purifier characterized by performing sterilization.
【0013】本発明で言う半透膜とは、水溶液に対して
溶質透過性を有するものである。すなわち、血液に対し
ては、血球成分を透過させないで他の溶質成分に対して
の透過機能をもつ膜である。膜を構成する素材は、再生
セルロース、酢酸セルロース等のセルロース及びセルロ
ース誘導体、キチン、キトサン等の天然多糖類、あるい
はその誘導体、ポリアクリロニトリル、ポリスルホン、
ポリエーテルスルホン、ポリアミド、アクリル系、メタ
クリル系重合体などの合成高分子、またはこれらの複合
体をあげることができるがセルロース系半透膜とくに酢
酸セルロース半透膜が好ましい。また膜形状としては、
平板状、中空糸状いずれの形状でも本発明の効果を妨げ
るものではない。The semipermeable membrane referred to in the present invention has a solute permeability to an aqueous solution. That is, it is a membrane that does not allow blood cell components to permeate blood and has a function of permeating other solute components. Materials constituting the membrane are regenerated cellulose, cellulose and cellulose derivatives such as cellulose acetate, natural polysaccharides such as chitin and chitosan, or derivatives thereof, polyacrylonitrile, polysulfone,
Synthetic polymers such as polyether sulfone, polyamide, acrylic and methacrylic polymers, and composites thereof can be mentioned, but a cellulose semipermeable membrane, particularly a cellulose acetate semipermeable membrane is preferable. In addition, as the film shape,
Either flat plate shape or hollow fiber shape does not impair the effects of the present invention.
【0014】血液浄化器内部に充填する多価カルボン酸
は、クエン酸、シュウ酸、イミノ二酢酸、アミノ二酢酸
およびこれらの塩などがあげられるが、医療用材料とし
ての安全性からはクエン酸を用いることが望ましい。Examples of the polyvalent carboxylic acid to be filled in the blood purifier include citric acid, oxalic acid, iminodiacetic acid, aminodiacetic acid and salts thereof, but citric acid is a safe material for medical use. Is preferred.
【0015】放射線滅菌時に起こる膜素材、装置部材の
劣化は、放射線エネルギーにより資材分子が光化学反応
を起こし、それにより生じたラジカルが連鎖反応をとも
たって重合体の分解を引き起こすことによる。放射線に
よる滅菌効果もこれと類似の反応機構により細菌の破壊
を起こさせているため、細菌の殺傷にはどうしても素材
の破壊を伴うことになる。またこれらの反応は、必ずし
も放射線照射中のみに起こるものではなく、照射が終了
した後にも自動酸化機構により経時的に劣化が進行する
こともありうる。Deterioration of the film material and the device member caused by radiation sterilization is caused by photochemical reaction of material molecules by radiation energy, and radicals generated thereby cause chain reaction and decomposition of the polymer. Since the sterilization effect by radiation causes the destruction of bacteria by a similar reaction mechanism, killing bacteria inevitably involves destruction of the material. Further, these reactions do not always occur only during irradiation of radiation, and deterioration may progress over time due to the autoxidation mechanism even after the irradiation is completed.
【0016】有機高分子材料は、その構造中にエーテ
ル、エステル、ケトン、アルコール、アミドなどの分子
構造を多く有しておりラジカルの攻撃を受けやすい素材
であるといえる。したがって、放射線に対する耐性は決
して良いとは言えず酸化劣化を起こしやすい面を持って
いる。通常樹脂加工の分野では、これらの酸化劣化を防
ぐために材料中に、フェノール系、リン系、ピペラジン
系などの酸化防止剤を含有させることが行われている
が、血液浄化半透膜にあっては、医療用途としての安全
性上、これらの成分を添加することは好ましくない。こ
のような半透膜材料の放射線に対する弱点を克服し、か
つ従来から有する優れた血液浄化用膜としての特性を維
持させるための滅菌方法として本発明を位置づけること
ができる。半透膜の劣化は、膜透過性の変化、素材とし
ての強度、伸度の低下及び溶出物等の増加として顕著に
現れることから、これらの変化の程度により劣化状態を
評価することができる。The organic polymer material has many molecular structures such as ethers, esters, ketones, alcohols and amides in its structure and can be said to be a material which is easily attacked by radicals. Therefore, it cannot be said that the resistance to radiation is good, and it has a surface that is prone to oxidative deterioration. In the field of resin processing, it is common practice to include phenolic, phosphorus, piperazine, and other antioxidants in materials to prevent these oxidative deteriorations. In terms of safety for medical use, it is not preferable to add these components. The present invention can be positioned as a sterilization method for overcoming the weakness of such a semipermeable membrane material against radiation and maintaining the excellent characteristics as a conventional blood purification membrane. Since the deterioration of the semipermeable membrane significantly appears as a change in membrane permeability, strength as a material, a decrease in elongation, and an increase in eluate, etc., the deterioration state can be evaluated by the degree of these changes.
【0017】これらの酸化反応は、すべて極微量の重金
属(鉄、銅、コバルトなど)により触媒され飛躍的に反
応が進行することが知られている。従って、これらの微
量成分が血液浄化膜装置内に残留すれば、半透膜の劣化
促進につながることは明らかである。しかしながら、原
料重合体の製造、精製過程、あるいは膜への成形加工過
程において、これらの重金属が添加あるいは混入され、
かなりの除去操作を行っても微量に残留することは避け
られない。現実的には、ppbオーダー以下に低減する
ことは、工業生産の立場からは不可能に近い。It is known that all of these oxidation reactions are dramatically catalyzed by an extremely small amount of heavy metals (iron, copper, cobalt, etc.). Therefore, it is clear that if these trace components remain in the blood purification membrane device, the deterioration of the semipermeable membrane is promoted. However, in the production of the raw material polymer, the purification process, or the process of forming into a film, these heavy metals are added or mixed,
It is inevitable that a small amount remains even after a considerable removal operation. In reality, it is almost impossible to reduce the ppb order or less from the viewpoint of industrial production.
【0018】本発明では、血液浄化器内部に多価カルボ
ン酸水溶液を充填し、半透膜をこの水溶液に浸漬させた
状態で放射線を照射するとしている。多価カルボン酸
は、半透膜に残留している水溶出性重金属に対してキレ
ート効果により酸化の触媒能を低減し半透膜の劣化を抑
えることができる。重金属は、水不溶性すなわちイオン
化していない状態では通常は酸化の触媒能を持たない
が、重金属周囲の重合体が酸素、熱、光などにより酸化
反応を起こした結果イオン化し触媒となる。従って、γ
線での重合体のラジカル反応により、重金属はイオン化
し半透膜劣化が加速的に進行する危険性がある。また、
イオン化した重金属は周りに水があると可溶化しバルク
水に溶出してくるため、本発明では、これらの溶出金属
の不活性化に強い効果が期待される。またこれらの多価
カルボン酸水溶液は、使用時には生理食塩水等で置換処
理され、洗い流され、また幾分かの量が残留したとして
も、実質的に、生体に対しては無害である。In the present invention, the inside of the blood purifier is filled with a polyvalent carboxylic acid aqueous solution, and the semi-permeable membrane is immersed in this aqueous solution and the radiation is applied. The polycarboxylic acid can reduce the catalytic ability of oxidation by a chelating effect on the water-eluting heavy metal remaining in the semipermeable membrane and suppress the deterioration of the semipermeable membrane. Heavy metals usually have no catalytic ability for oxidation in a water-insoluble state, that is, in a non-ionized state, but as a result of the oxidation reaction of the polymer around the heavy metal due to oxygen, heat, light, etc., the heavy metal becomes a catalyst. Therefore, γ
Due to the radical reaction of the polymer on the lines, there is a risk that the heavy metal will be ionized and the semipermeable membrane deterioration will accelerate. Also,
Ionized heavy metals are solubilized in the presence of water around them and are eluted into bulk water, so that the present invention is expected to have a strong effect on the inactivation of these eluted metals. In addition, these polyvalent carboxylic acid aqueous solutions are practically harmless to the living body even when they are replaced with physiological saline or the like at the time of use, washed off, and some amount remains.
【0019】水溶液中の多価カルボン酸濃度は、0.0
1〜5.0%が好ましく、さらに好ましくは0.05〜
1.0%である。5.0%以上の濃度では、多価カルボ
ン酸自体による水溶液のpHの低下、生理食塩水による
置換洗浄処理が不完全な場合の残留量の増加などが顕著
になるため好ましくない。The concentration of polyvalent carboxylic acid in the aqueous solution is 0.0
1 to 5.0% is preferable, and more preferably 0.05 to
It is 1.0%. A concentration of 5.0% or more is not preferable because the pH of the aqueous solution is lowered by the polycarboxylic acid itself and the residual amount is increased when the replacement washing treatment with physiological saline is incomplete.
【0020】血液浄化器に、多価カルボン酸水溶液を充
填する方法としては、水溶液を該浄化器の血液流出入
口、または浄化用流体流出入口より注入し、密栓をする
ことにより達成されうる。充填する水溶液量は、実質的
に半透膜が均一に湿潤状態になる量で十分であるが、内
部に空気等の酸素が存在すると酸化促進いつながるため
内部に空間ができる場合は、酸素が混入しないように配
慮するべきである。また、血液浄化器を構成する半透膜
以外の部材であるポッティング部のポリウレタン素材、
容器素材に対しても放射線に対して劣化性の少ない素材
を選択しなければならないことは言うまでもない。The method for filling the blood purifier with the aqueous solution of polycarboxylic acid can be achieved by injecting the aqueous solution from the blood outflow port or the purifying fluid outflow port of the purifier and sealing it. The amount of the aqueous solution to be filled is sufficient so that the semipermeable membrane is substantially evenly moistened, but the presence of oxygen such as air in the interior promotes oxidation, which leads to oxidation. Care should be taken to prevent contamination. In addition, the polyurethane material of the potting portion, which is a member other than the semipermeable membrane that constitutes the blood purifier,
It goes without saying that it is necessary to select a material that is less likely to be deteriorated by radiation as a container material.
【0021】以上に述べられた方法により、放射線によ
り半透膜とくにセルロース系半透膜からなる血液浄化器
を膜性能等の劣化を起こすことなく滅菌処理することが
可能となる。以下に、実施例によって説明するが、その
前に実施例において行うサンプルの調整法、評価法につ
いて述べる。まず本発明で使用するとくにセルロース系
半透膜の製造方法について記しておく。セルロース系重
合体から血液浄化膜を作製する手段としては、セルロー
ス系重合体を溶媒、あるいは溶媒、貧溶媒の混合液から
なる溶剤に溶解してドープ原液を調製し、これをノズル
から吐出させ凝固浴中で相分離による膜形成を行わせる
方法が挙げられる。この方法では、膜の空孔の孔径分布
を狭くし、シャープな血液成分の分画特性を得ることが
可能となる。また、適当なドープ条件、凝固条件を選ぶ
ことによって様々な溶質分離特性を膜に与えることが可
能である。本実施例では、セルロース系重合体として、
三酢酸セルロースを用いて中空糸型の半透膜を作製し
た。また、市販の再生セルロース製人工腎臓透析器につ
いても評価した。According to the method described above, it becomes possible to sterilize a blood purifier composed of a semipermeable membrane, particularly a cellulosic semipermeable membrane, by radiation without causing deterioration of membrane performance and the like. Examples will be described below, but before that, a sample adjusting method and an evaluating method performed in the examples will be described. First, the method for producing a cellulosic semipermeable membrane used in the present invention will be described. As a means for producing a blood purification membrane from a cellulosic polymer, a dope stock solution is prepared by dissolving the cellulosic polymer in a solvent or a solvent consisting of a solvent and a poor solvent, and then coagulating the dope by discharging it from a nozzle. A method of forming a film by phase separation in a bath can be mentioned. With this method, it is possible to narrow the pore size distribution of the pores of the membrane and obtain a sharp blood component fractionation characteristic. Further, it is possible to give various solute separation characteristics to the membrane by selecting appropriate doping conditions and solidification conditions. In this example, as the cellulose-based polymer,
A hollow fiber type semipermeable membrane was prepared using cellulose triacetate. In addition, a commercially available regenerated cellulose artificial kidney dialyzer was also evaluated.
【0022】中空糸の調製法 セルロース系重合体が10〜30重量%かつ溶媒として
N−メチルピロリドン(NMP)を用い、貧溶媒として
エチレングリコール・トリエチレングリコール等からな
る紡糸ドープを調製し、二重管ノズルより芯液と共に吐
出させ中空化し、上記ドープの溶媒、貧溶媒と同じ混合
系成分からなる凝固浴中で凝固させ、中空糸膜を作製し
た。中空糸は、内径200μm、膜厚15μmに制御し
て紡糸を行った。Preparation Method of Hollow Fiber A cellulosic polymer is used in an amount of 10 to 30% by weight, N-methylpyrrolidone (NMP) is used as a solvent, and a spinning dope composed of ethylene glycol, triethylene glycol or the like is used as a poor solvent. A hollow fiber membrane was produced by discharging the mixture from the heavy tube nozzle together with the core liquid to make it hollow, and coagulating it in a coagulation bath consisting of the same mixed system components as the solvent of the dope and the poor solvent. The hollow fiber was spun while controlling the inner diameter to 200 μm and the film thickness to 15 μm.
【0023】血液浄化器の作製法 ポリカーボネート製のケースのなかに前記中空糸を約1
0000本挿入し両端部をジイソシアナート及びヒマシ
油系ジオールからなるウレタン樹脂で固定するとともに
切断開口させ、流入口を有するキャップを装着した。こ
の血液浄化器の浄化用流体流出入口から、所定の濃度の
多価カルボン酸水溶液を装着内に充填し全開口部を、樹
脂栓で閉じた。その後、血液浄化器全体をポリエチレン
製の袋に入れ真空包装を施し、所定の線量のγ線を照射
した。照射線量は、滅菌保証には十分な25kGy,5
0kGyで実施した。Method for manufacturing blood purifier In a case made of polycarbonate, about 1 hollow fiber is used.
0000 pieces were inserted, both ends were fixed with a urethane resin composed of diisocyanate and castor oil-based diol, cut and opened, and a cap having an inlet was attached. From the purifying fluid outlet / inlet of this blood purifier, a polyvalent carboxylic acid aqueous solution having a predetermined concentration was filled into the inside of the attachment, and all openings were closed with a resin stopper. Then, the whole blood purifier was put in a polyethylene bag, vacuum-packaged, and irradiated with a predetermined dose of γ-rays. The irradiation dose is 25 kGy, 5 which is sufficient for sterilization assurance.
It was carried out at 0 kGy.
【0024】セルロース系半透膜の劣化状態の評価 装置内より封入液を自然落下で除去した後、中空糸のみ
を取り出して湿潤状態での糸質(降伏、破断の強度、伸
度)の測定に供した。またその他の溶出物試験に関して
は、透析型人工腎臓承認基準(日本医療用プラスチック
協会、日本人工臓器工業協会発行)に準じて実施した。Evaluation of Deteriorated State of Cellulose-based Semipermeable Membrane After removing the enclosed liquid from the device by natural fall, only hollow fibers were taken out and the yarn quality (yield, breaking strength, elongation) in wet state was measured. I went to The other eluate tests were performed according to the dialysis type artificial kidney approval standard (published by the Japan Medical Plastics Association and the Japan Artificial Organs Association).
【0025】[0025]
【実施例】以下実施例を挙げて本発明を説明する。再生
セルロース中空糸膜及び三酢酸セルロース中空糸膜を用
いた人工血液浄化器にクエン酸0.1%水溶液を充填
し、全開口部を樹脂栓で密封した後該血液浄化器をポリ
エチレン製の袋に入れ真空包装し、25kGy及び50
kGyの線量によるγ滅菌を施した。比較例として充填
なし、脱酸素水のみ充填についても同様のテストを行っ
た。結果を表1、表2に示した。クエン酸水溶液の系で
は、表に示したように、溶出物試験でのpH低下、紫外
線吸光度の上昇、糸質の低下等が軽微に抑えられてい
る。従って、本発明の目的とする半透膜の劣化の低減が
実現されていることを示す。また、半透膜の透水性は、
再生セルロースでは、6ml/hr・mmHg・m2 、
三酢酸セルロースでは、30ml/hr・mmHg・m
2 のものを使用したが、γ線照射後においても透水性の
有意な変化は観察されなかった。EXAMPLES The present invention will be described below with reference to examples. An artificial blood purifier using a regenerated cellulose hollow fiber membrane and a cellulose triacetate hollow fiber membrane was filled with a 0.1% citric acid aqueous solution, and the whole opening was sealed with a resin stopper, and then the blood purifier was made into a polyethylene bag. Put in a vacuum package, 25kGy and 50
Gamma sterilization was performed with a dose of kGy. As a comparative example, the same test was performed with no filling and with deoxygenated water only. The results are shown in Tables 1 and 2. In the citric acid aqueous solution system, as shown in the table, the pH drop, the ultraviolet absorbance increase, the thread quality drop, etc. in the eluate test are slightly suppressed. Therefore, it is shown that the reduction of the deterioration of the semipermeable membrane which is the object of the present invention is realized. In addition, the water permeability of the semipermeable membrane is
For regenerated cellulose, 6 ml / hr · mmHg · m 2 ,
For cellulose triacetate, 30 ml / hr · mmHg · m
No. 2 was used, but no significant change in water permeability was observed even after γ-ray irradiation.
【0026】[0026]
【表1】 [Table 1]
【0027】[0027]
【表2】 [Table 2]
【0028】[0028]
【発明の効果】以上の説明から明らかなように、本発明
により、半透膜劣化の低減された放射線滅菌血液浄化器
を提供することが可能になる。As is apparent from the above description, according to the present invention, it is possible to provide a radiation sterilized blood purifier with reduced deterioration of semipermeable membrane.
Claims (1)
液浄化内部に多価カルボン酸の水溶液を充填密閉し、該
半透膜が多価カルボン酸水溶液により浸漬された状態で
放射線滅菌を施すことを特徴とする血液浄化器の滅菌
法。1. A blood purifier using a semipermeable membrane, wherein blood purification is filled and sealed with an aqueous solution of polyvalent carboxylic acid, and radiation sterilization is performed with the semipermeable membrane immersed in the polyvalent carboxylic acid aqueous solution. A method for sterilizing a blood purifier characterized by applying.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6126401A JPH07328111A (en) | 1994-06-08 | 1994-06-08 | Sterilization method of blood purifier |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6126401A JPH07328111A (en) | 1994-06-08 | 1994-06-08 | Sterilization method of blood purifier |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000215957A Division JP2001061960A (en) | 2000-07-17 | 2000-07-17 | Blood purifying film |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH07328111A true JPH07328111A (en) | 1995-12-19 |
Family
ID=14934249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6126401A Pending JPH07328111A (en) | 1994-06-08 | 1994-06-08 | Sterilization method of blood purifier |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH07328111A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006271430A (en) * | 2005-03-28 | 2006-10-12 | Toyobo Co Ltd | Sterilization method of blood purification module |
| JP2007296145A (en) * | 2006-04-28 | 2007-11-15 | Toyobo Co Ltd | Blood purifier |
-
1994
- 1994-06-08 JP JP6126401A patent/JPH07328111A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006271430A (en) * | 2005-03-28 | 2006-10-12 | Toyobo Co Ltd | Sterilization method of blood purification module |
| JP2007296145A (en) * | 2006-04-28 | 2007-11-15 | Toyobo Co Ltd | Blood purifier |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2590687B1 (en) | Use of a sterilization agent for enhancing hemocompatibility | |
| JP4846587B2 (en) | Polysulfone-based selectively permeable hollow fiber membrane module and method for producing the same | |
| JP4848278B2 (en) | Highly permeable hollow fiber membrane blood purifier and method for producing the same | |
| JP4453248B2 (en) | Method for producing hollow fiber membrane and hollow fiber membrane module | |
| US4148606A (en) | Sterilization of dialyzer | |
| WO2006107014A1 (en) | Blood purifier | |
| JPS59211459A (en) | Pasturization of blood treating device | |
| JP2010233999A (en) | Blood purifier | |
| JP3928910B2 (en) | Polysulfone blood treatment module | |
| JP4873665B2 (en) | Hollow fiber membrane for blood purification | |
| JP3357262B2 (en) | Hollow fiber membrane type body fluid purifying device and method of manufacturing the same | |
| CN101102802A (en) | Blood purifier package and method for producing same | |
| JPH07328111A (en) | Sterilization method of blood purifier | |
| JPH07328112A (en) | Sterilization method for blood purifier | |
| JP2001061960A (en) | Blood purifying film | |
| JP2013009962A (en) | Hollow fiber membrane type hemocatharsis apparatus | |
| JP2779257B2 (en) | Blood processing equipment sterilization method | |
| JP4483651B2 (en) | Sterilization method of blood purification module | |
| JP4738728B2 (en) | Hollow fiber blood processor and sterilization packaging method thereof | |
| JP2010233987A (en) | Blood purifier | |
| JP4666248B2 (en) | High strength high water permeability hollow fiber membrane blood purifier | |
| JP2006288415A (en) | Bundle of polysulfone-based permselective hollow fiber membrane and hemocatharsis apparatus | |
| JP2007296145A (en) | Blood purifier | |
| JP2006230905A (en) | Blood purifier | |
| JP2010017712A (en) | Hollow fiber membrane and hollow fiber membrane module |